Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients
- PMID: 17224217
- DOI: 10.1016/j.vaccine.2006.11.019
Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients
Abstract
To study the responses of chronic hepatitis B patients to yeast-derived HBsAg-HBIG complexes (YIC) and the mechanisms involved, twenty HBeAg-positive chronic hepatitis B patients were immunized with 60microg of YIC or alum as the control at 4-week intervals, for 24 weeks. Five of ten patients responded to 60microg YIC immunization showing > or =2 logs decrease of serum HBV DNA with loss or marked reduction of HBeAg and appearance of anti-HBe; two of these patients developed anti-HBs. Flares of alanine aminotransferase were observed in 4 of the 5 responders, and in 2 out of 10 control patients. HBsAg-stimulated peripheral blood mononuclear cells (PBMCs) secreted Th1/Th2 cytokines around 24 weeks after immunization. Dendritic cells incubated with YIC showed the highest levels of IL-12 secretion and up-regulation of functional markers. Thus, the therapeutic effect of YIC is associated with cytolytic and non-cytolytic responses in patients.
Similar articles
-
Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine.Vaccine. 2010 Nov 29;28(51):8169-74. doi: 10.1016/j.vaccine.2010.09.093. Epub 2010 Oct 28. Vaccine. 2010. PMID: 20937312 Clinical Trial.
-
[Advances on antigen-antibody immunogenic complex therapeutic vaccine for viral hepatitis B].Zhonghua Gan Zang Bing Za Zhi. 2009 Sep;17(9):718-20. Zhonghua Gan Zang Bing Za Zhi. 2009. PMID: 19785971 Review. Chinese. No abstract available.
-
Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse.Hepatology. 2000 Feb;31(2):480-7. doi: 10.1002/hep.510310231. Hepatology. 2000. PMID: 10655274
-
Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.J Hepatol. 2013 Sep;59(3):450-6. doi: 10.1016/j.jhep.2013.05.003. Epub 2013 May 11. J Hepatol. 2013. PMID: 23669281 Clinical Trial.
-
Antigen-antibody complex as therapeutic vaccine for viral hepatitis B.Int Rev Immunol. 1999;18(3):251-8. doi: 10.3109/08830189909043028. Int Rev Immunol. 1999. PMID: 10614727 Review.
Cited by
-
The Investigation of Hepatitis B Vaccine Immune Responses in Occult Hepatitis B Virus-Infected Patients.Front Immunol. 2022 May 27;13:903685. doi: 10.3389/fimmu.2022.903685. eCollection 2022. Front Immunol. 2022. PMID: 35747142 Free PMC article. Clinical Trial.
-
HBV life cycle and novel drug targets.Hepatol Int. 2011 Jun;5(2):644-53. doi: 10.1007/s12072-011-9261-3. Epub 2011 Mar 8. Hepatol Int. 2011. PMID: 21484123 Free PMC article.
-
Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck.Med Microbiol Immunol. 2015 Feb;204(1):103-14. doi: 10.1007/s00430-014-0379-5. Epub 2014 Dec 23. Med Microbiol Immunol. 2015. PMID: 25535101 Free PMC article. Review.
-
Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.Hum Vaccin Immunother. 2017 Sep 2;13(9):1989-1996. doi: 10.1080/21645515.2017.1335840. Epub 2017 Jun 30. Hum Vaccin Immunother. 2017. PMID: 28665747 Free PMC article.
-
A Pilot Study of MicroRNAs Expression Profile in Serum and HBsAg Particles: Predictors of Therapeutic Vaccine Efficacy in Chronic Hepatitis B Patients.Medicine (Baltimore). 2016 Jan;95(2):e2511. doi: 10.1097/MD.0000000000002511. Medicine (Baltimore). 2016. PMID: 26765470 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
